Alveltamig
Alveltamig (ZG006) is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3. Alveltamig has two distinct DLL3 epitopes, and bridges tumor cells and T cells by strongly binding to DLL3 on tumor cells and CD3 on T cells, thereby mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the study of small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC) [1].
Product Specifications
Product Name Alternative
ZG006
UNSPSC
12352005
Target
CD3
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Alveltamig]
References & Citations
[1]Qiming Wang, et al. A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma. Journal of Clinical Oncology. Volume 43, Number 16_suppl.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC401551 20 µg
Kv2.1 (KCNB1) (NM_004975) Human Over-expression Lysate
Sign In for Pricing
View Details 
MT22F4-MAL 10x 96 Well Plates
Maleimide Coated - 96 well plates - 8 Well Strips on 12 x 8 frame - Clear PS
Sign In for Pricing
View Details 